As of June 17, 2025, Alnylam Pharmaceuticals Inc (ALNY) reports a EV/EBITDA of -830.88.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Alnylam Pharmaceuticals Inc's EV/EBITDA to Peers
To better understand Alnylam Pharmaceuticals Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Alnylam Pharmaceuticals Inc (ALNY) | -830.88 |
| TG Therapeutics Inc (TGTX) | 81.93 |
| Incyte Corp (INCY) | 47.47 |
| Halozyme Therapeutics Inc (HALO) | 10.63 |
| Emergent BioSolutions Inc (EBS) | 8.11 |
| United Therapeutics Corp (UTHR) | 7.60 |
Compared to its competitors, Alnylam Pharmaceuticals Inc's EV/EBITDA is lower than all peers, which may indicate undervaluation or market concerns about future performance.